Literature DB >> 21358525

An articular-based approach to Kienbock avascular necrosis of the lunate.

Gregory I Bain1, Adam Durrant.   

Abstract

There are 3 pathologic phases of Kienbock disease: early vascular, intermediate osseous, and late chondral. Most of the earlier investigators have used Lichtman osseous radiologic classification. We have used an articular based approach to assess and manage Kienbock disease. The Bain and Begg arthroscopic classification is based on the number of nonfunctional articular surfaces of the lunate and adjacent articulations. The spectrum of articular changes span from grade 0, all normal articular surfaces; grade 1, involvement of the proximal lunate which is often soft and indentable with a false floor; grade 2a, lunate changes and secondary changes on the lunate facet; grade 2b, coronal lunate fracture produces involvement of the midcarpal joint; and grade 3s and 4, involvement of 3 and subsequently 4 of the perilunate articular surfaces. Arthroscopic findings have shown that radiographs often underestimate articular changes and frequently changed the treatment recommendation. Eighty-two percent of cases had at least 1 nonfunctional articulation, whereas 61% had at least 2 nonfunctional articulations. The aim of surgical treatment is to maintain functional motion with normal articulations. The articular-based classification directs treatment based on sound surgical principles. If all articular surfaces are intact, then a procedure that does not violate the articular surfaces is indicated (eg, synovectomy, vascularized bone graft, forage or joint leveling procedure). With nonfunctioning articular surfaces, an articular reconstructive procedure is required to leave the carpus mobile with only functional articular surfaces. (eg, proximal row carpectomy, radioscapholunate fusion, lunate replacement, or hemiarthroplasty). More extensive joint involvement requires a salvage procedure. This articular-based approach was developed for Kienbock disease but is universally applicable to all forms of avascular necrosis and can be used with advanced imaging modalities.

Entities:  

Mesh:

Year:  2011        PMID: 21358525     DOI: 10.1097/BTH.0b013e31820e82e8

Source DB:  PubMed          Journal:  Tech Hand Up Extrem Surg        ISSN: 1089-3393


  8 in total

1.  Decision making for partial carpal fusions.

Authors:  Gregory Ian Bain; Duncan Thomas McGuire
Journal:  J Wrist Surg       Date:  2012-11

2.  In Vivo High-Resolution Trabecular Microstructure of Kienböck Lunate before and after Radial Shortening: A Case Report.

Authors:  Marion Burnier; Guillaume Herzberg; Roland Chapurlat; Stéphanie Boutroy
Journal:  J Wrist Surg       Date:  2016-04-13

3.  Kienböck Disease: A New Algorithm for the 21st Century.

Authors:  David M Lichtman; William F Pientka; Gregory Ian Bain
Journal:  J Wrist Surg       Date:  2016-10-27

4.  Lunate Reconstruction Using Osteochondral Vascularized Graft in Kienböck's Disease.

Authors:  Òscar Izquierdo; Pilar Aparicio; Enric Domínguez; Juan Castellanos
Journal:  J Hand Microsurg       Date:  2018-03-20

5.  Vascularized bone grafts for the treatment of carpal bone pathology.

Authors:  Brian M Derby; Peter M Murray; Alexander Y Shin; Reuben A Bueno; Christophe L Mathoulin; Tim Ade; Michael W Neumeister
Journal:  Hand (N Y)       Date:  2013-03

6.  Single-Cut Single-Screw Capitate-Shortening Osteotomy for Kienbock's Disease.

Authors:  Gregory I Bain; Sathya Vamsi Krishna; Simon Bruce Murdoch MacLean; Parth Agrawal
Journal:  J Wrist Surg       Date:  2020-05-01

Review 7.  Treatments for Kienböck disease: what the radiologist needs to know.

Authors:  Carissa White; Prosper Benhaim; Benjamin Plotkin
Journal:  Skeletal Radiol       Date:  2016-01-23       Impact factor: 2.199

Review 8.  Recent Advances in Assessment and Treatment in Kienböck's Disease.

Authors:  Karol Chojnowski; Mikołaj Opiełka; Miłosz Piotrowicz; Bartosz Kamil Sobocki; Justyna Napora; Filip Dąbrowski; Maciej Piotrowski; Tomasz Mazurek
Journal:  J Clin Med       Date:  2022-01-27       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.